Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (EN, Sanofi-Aventis)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (GlobeNewswire)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (EN, Sanofi-Aventis)
30.05.24	Press Release: Sanofi completes acquisition of Inhibrx, Inc. (GlobeNewswire)
30.05.24	Press Release: Sanofi completes acquisition of Inhibrx, Inc. (EN, Sanofi-Aventis)
27.05.24	Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment (RTTNews)
27.05.24	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
27.05.24	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma (EN, Sanofi-Aventis)
22.05.24	Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma (EN, Sanofi-Aventis)
21.05.24	Sanofi, OpenAI To Build AI Software To Boost Drug Development (RTTNews)
21.05.24	Sanofi, Formation Bio, OpenAI Announce AI Collaboration (RTTNews)
21.05.24	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration (EN, Sanofi-Aventis)
21.05.24	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration (GlobeNewswire)
20.05.24	Sanofi: Information concerning the total number of voting rights and shares - April 2024 (GlobeNewswire)
20.05.24	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (EN, Sanofi-Aventis)
20.05.24	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (GlobeNewswire)
13.05.24	Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod (RTTNews)
13.05.24	Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis (RTTNews)
13.05.24	Sanofi To Invest Over EUR 1 Bln Further For Biomanufacturing In France (RTTNews)
13.05.24	Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty (EN, Sanofi-Aventis)
13.05.24	Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty (GlobeNewswire)
10.05.24	Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine (RTTNews)
10.05.24	Sanofi Strikes COVID-19 Vaccine Agreement With Novavax; To Take Minority Stake (RTTNews)
10.05.24	Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines (EN, Sanofi-Aventis)
10.05.24	Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines (GlobeNewswire)
02.05.24	Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations (EN, Sanofi-Aventis)
02.05.24	Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations (GlobeNewswire)
30.04.24	Press Release: Annual General Meeting of April 30, 2024 (EN, Sanofi-Aventis)
30.04.24	Press Release: Annual General Meeting of April 30, 2024 (GlobeNewswire)
26.04.24	Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases (EN, Sanofi-Aventis)
25.04.24	Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up (RTTNews)
25.04.24	Sanofi Q1 Profit Drops, Sales Rise; Confirms FY24 Outlook (RTTNews)
25.04.24	Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance (GlobeNewswire)
25.04.24	Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance (EN, Sanofi-Aventis)
23.04.24	Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia (RTTNews)
23.04.24	Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia (EN, Sanofi-Aventis)
23.04.24	Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia (GlobeNewswire)
17.04.24	Why IGM Biosciences Is Rising In Pre-market? (RTTNews)
17.04.24	Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (EN, Sanofi-Aventis)
17.04.24	Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (GlobeNewswire)
12.04.24	Sanofi: Information concerning the total number of voting rights and shares - March 2024 (GlobeNewswire)
08.04.24	Sanofi - AGM 30.04.2024 - Availability of Preparatory documents (GlobeNewswire)
22.03.24	Press Release: Availability of the Q1 2024 Memorandum for modelling purposes (EN, Sanofi-Aventis)
22.03.24	Press Release: Availability of the Q1 2024 Memorandum for modelling purposes (GlobeNewswire)
15.03.24	Sanofi: Information concerning the total number of voting rights and shares - February 2024 (GlobeNewswire)
11.03.24	Sanofi's Phase 2b Results Support Amlitelimab's Potential In Atopic Dermatitis (RTTNews)
11.03.24	Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis (GlobeNewswire)
11.03.24	Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis (EN, Sanofi-Aventis)
24.02.24	Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria (GlobeNewswire)
24.02.24	Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria (EN, Sanofi-Aventis)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
29.12.24		Roche-CEO bescheinigt Pharmakonzern gesundes Geschäft
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Dow Jones aktuell: Dow Jones verliert am Freitagnachmittag
27.12.24		Schwacher Wochentag in New York: Dow Jones verbucht am Freitagmittag Verluste
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester